The specter of generic rivalry has repeatedly loomed above copyright’s iconic drug, Sildenafil, raising questions about the outlook of connected medicinal holdings. While initial years saw substantial profits, the patent end has allowed the door for cheaper alternatives, potentially diminishing earnings and presenting a genuine hazard for shareho